Helicos BioSciences (HLCS) carries out successful landmark study of molecule
Helicos BioSciences (NYSE: HLCS) announced the publication of a landmark study in which HLCS's True Single Molecule Sequencing technology was used to directly sequence individual molecules of RNA. The paper appeared yesterday in the on-line edition of Nature and will appear in an upcoming 2009 print issue of Nature. HLCS stock moved up by 12.75% in early trade to $2.75 on high volumes, thus showing signs of bullish trend.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Long Ideas Small Cap Analysis Technicals Trading Ideas